The late Dr. Paul Walfish, a pioneer in the treatment of thyroid disease, helped put Mount Sinai Hospital on the map as a leader in thyroid cancer treatment and management.
After establishing the Nuclear Medicine Department at Mount Sinai in 1965, Dr. Walfish and his colleagues spearheaded studies for the early detection of thyroid cancer using fine needle biopsy and ultrasound. He also pioneered a new testing method that can determine whether radioactive iodine treatment is required following thyroid cancer surgery.
These new techniques armed clinicians with enhanced tools and knowledge, revolutionizing the management and treatment of thyroid cancer in North America.
Dr. Walfish’s discoveries reshaped thyroid cancer care around the world. In 1990, he was named to the Order of Canada for his contributions to medicine. In 2007, he received the Order of Ontario for establishing a newborn screening program to detect congenital hypothyroidism in infants — a condition that can cause brain damage, mental disability and growth failure. The test has now been adopted by hospitals around the world.
As a clinician and researcher, Dr. Walfish exemplified how research conducted within a hospital setting can be translated into innovative approaches to treatment that improve patients’ lives.
Like Dr. Walfish himself, future holders of the Dr. Paul Walfish Chair in Head & Neck Cancer will be innovative clinical and academic leaders in the field. The Walfish Chair will help Sinai Health to attract the brightest minds in thyroid research and care.
After establishing the Nuclear Medicine Department at Mount Sinai in 1965, Dr. Walfish and his colleagues spearheaded studies for the early detection of thyroid cancer using fine needle biopsy and ultrasound. He also pioneered a new testing method that can determine whether radioactive iodine treatment is required following thyroid cancer surgery.
These new techniques armed clinicians with enhanced tools and knowledge, revolutionizing the management and treatment of thyroid cancer in North America.
Dr. Walfish’s discoveries reshaped thyroid cancer care around the world. In 1990, he was named to the Order of Canada for his contributions to medicine. In 2007, he received the Order of Ontario for establishing a newborn screening program to detect congenital hypothyroidism in infants — a condition that can cause brain damage, mental disability and growth failure. The test has now been adopted by hospitals around the world.
As a clinician and researcher, Dr. Walfish exemplified how research conducted within a hospital setting can be translated into innovative approaches to treatment that improve patients’ lives.
Like Dr. Walfish himself, future holders of the Dr. Paul Walfish Chair in Head & Neck Cancer will be innovative clinical and academic leaders in the field. The Walfish Chair will help Sinai Health to attract the brightest minds in thyroid research and care.
After establishing the Nuclear Medicine Department at Mount Sinai in 1965, Dr. Walfish and his colleagues spearheaded studies for the early detection of thyroid cancer using fine needle biopsy and ultrasound. He also pioneered a new testing method that can determine whether radioactive iodine treatment is required following thyroid cancer surgery.
These new techniques armed clinicians with enhanced tools and knowledge, revolutionizing the management and treatment of thyroid cancer in North America.
Dr. Walfish’s discoveries reshaped thyroid cancer care around the world. In 1990, he was named to the Order of Canada for his contributions to medicine. In 2007, he received the Order of Ontario for establishing a newborn screening program to detect congenital hypothyroidism in infants — a condition that can cause brain damage, mental disability and growth failure. The test has now been adopted by hospitals around the world.
As a clinician and researcher, Dr. Walfish exemplified how research conducted within a hospital setting can be translated into innovative approaches to treatment that improve patients’ lives.
Like Dr. Walfish himself, future holders of the Dr. Paul Walfish Chair in Head & Neck Cancer will be innovative clinical and academic leaders in the field. The Walfish Chair will help Sinai Health to attract the brightest minds in thyroid research and care.
Dr. Walfish spearheaded studies for the early detection of thyroid cancer using fine needle biopsy and ultrasound.
About Mount Sinai 100 Chairs
In 2023, Mount Sinai Hospital will mark its 100th anniversary. To honour the physicians and scientists who have made breakthrough discoveries and whose achievements have elevated Sinai Health’s reputation for world-class care, we are pleased to introduce our Mount Sinai 100 Chairs. These legacy chairs carry the names of Sinai Health’s most eminent trailblazers and will help recruit and fund the work of a new generation of clinicians and scientists, securing the next century of caring at Sinai Health. We invite you to help us imagine the next 100 years.
About Mount Sinai 100 Chairs
In 2023, Mount Sinai Hospital will mark its 100th anniversary. To honour the physicians and scientists who have made breakthrough discoveries and whose achievements have elevated Sinai Health’s reputation for world-class care, we are pleased to introduce our Mount Sinai 100 Chairs. These legacy chairs carry the names of Sinai Health’s most eminent trailblazers and will help recruit and fund the work of a new generation of clinicians and scientists, securing the next century of caring at Sinai Health. We invite you to help us imagine the next 100 years.
About Mount Sinai 100 Chairs
In 2023, Mount Sinai Hospital will mark its 100th anniversary. To honour the physicians and scientists who have made breakthrough discoveries and whose achievements have elevated Sinai Health’s reputation for world-class care, we are pleased to introduce our Mount Sinai 100 Chairs. These legacy chairs carry the names of Sinai Health’s most eminent trailblazers and will help recruit and fund the work of a new generation of clinicians and scientists, securing the next century of caring at Sinai Health. We invite you to help us imagine the next 100 years.
